Tregitope: Immunomodulation powerhouse

Human Immunology

Volumn 75, Issue 12, 2014, Pages 1139-1146

  Cousens, Leslie ^a   Najafian, Nader ^b,c   Martin, William D ^a   De Groot, Anne S ^a,d  

^a EpiVax Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

IVIg; Tolerance; Transplantation; Treg; Tregitope

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; EPITOPE; IMMUNOGLOBULIN; INTERLEUKIN 10; TREGITOPE; UNCLASSIFIED DRUG; CD86 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; HLA DR ANTIGEN; IL10 PROTEIN, HUMAN; IMMUNOGLOBULIN G; LILRB4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN TRANSPLANTATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PASSIVE IMMUNIZATION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, CELL SURFACE; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84922542853     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.10.012     Document Type: Article

References (45)

1. Cousens L.P., Su Y., McClaine E., Li X., Terry F., Smith R., et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diab Res 2013, 2013:621693.
2. Elyaman W., Khoury S.J., Scott D.W., De Groot A.S. Potential application of Tregitopes as immuno-modulating agents in multiple sclerosis. Neurol Res Int 2011, 2011:256460.
3. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
4. Apostolou I., Sarukhan A., Klein L., von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002, 3:756-763.
5. Leung M.W., Shen S., Lafaille J.J. TCR-dependent differentiation of thymic Foxp3+ cells is limited to small clonal sizes. J Exp Med 2009, 206:2121-2130.
6. Simons D.M., Picca C.C., Oh S., Perng O.A., Aitken M., Erikson J., et al. How specificity for self-peptides shapes the development and function of regulatory T cells. J Leukoc Biol 2010, 88:1099-1107.
7. Soukhareva N., Jiang Y., Scott D.W. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol 2006, 240:41-46.
8. Ephrem A., Chamat S., Miquel C., Fisson S., Mouthon L., Caligiuri G., et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
9. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010, 30:9-14.
10. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIg anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
11. Baum C.E., Mierzejewska B., Schroder P.M., Khattar M., Stepkowski S. Optimizing the use of regulatory T cells in allotransplantation: recent advances and future perspectives. Expert Rev Clin Immunol 2013, 9:1303-1314.
12. van Agteren M., Weimar W., de Weerd A.E., Te Boekhorst P.A., Ijzermans J.N., van de Wetering J., et al. The first fifty ABO blood group incompatible kidney transplantations: the Rotterdam experience. J Transplant 2014, 2014:913902.
13. Hui D.J., Basner-Tschakarjan E., Chen Y., Davidson R.J., Buchlis G., Yazicioglu M., et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther 2013, 21:1727-1737.
14. Su Y., Rossi R., De Groot A.S., Scott D.W. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol 2013, 94:377-383.
15. Mahnke K., Enk A.H. Dendritic cells: key cells for the induction of regulatory T cells?. Curr Top Microbiol Immunol 2005, 293:133-150.
16. Steinman R.M., Hawiger D., Liu K., Bonifaz L., Bonnyay D., Mahnke K., et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003, 987:15-25.
17. Thery C., Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001, 13:45-51.
18. Jung S., Unutmaz D., Wong P., Sano G., De los Santos K., Sparwasser T. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
19. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002, 23:445-449.
20. Heufler C., Koch F., Stanzl U., Topar G., Wysocka M., Trinchieri G., et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 2006, 26:659-668.
21. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
22. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
23. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997, 388:782-787.
24. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
25. de Heusch M., Oldenhove G., Urbain J., Thielemans K., Maliszewski C., Leo O., et al. Depending on their maturation state, splenic dendritic cells induce the differentiation of CD4(+) T lymphocytes into memory and/or effector cells in vivo. Eur J Immunol 2004, 34:1861-1869.
26. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008, 112:3303-3311.
27. Elyaman W., Bradshaw E.M., Uyttenhove C., Dardalhon V., Awasthi A., Imitola J., et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009, 106:12885-12890.
28. Grabert R.C., Cousens L.P., Smith J.A., Olson S., Gall J., Young W.B., et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006, 12:569-576.
29. Sandner S.E., Salama A.D., Houser S.L., Palmer E., Turka L.A., Sayegh M.H. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant 2003, 3:1242-1250.
30. Sayegh M.H., Wu Z., Hancock W.W., Langmuir P.B., Mata M., Sandner S., et al. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am J Transplant 2003, 3:381-389.
31. D'Addio F., Watanabe T., Elyaman W., Magee C.N., Yeung M.Y., Padera R.F., Rodig S.J., Murayama T., Tanaka K., Yuan X., Ueno T., Jurisch A., Mfarrej B., Akiba H., Yagita H., Najafian N. TIM-3: A novel regulatory molecule of alloimmune activation. J Immunol 2010, 185(10):5806-5819.
32. D'Addio F., Yuan X., Habicht A., Williams J., Ruzek M., Iacomini J., et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation 2010, 90:260-269.
33. Law J.P., Hirschkorn D.F., Owen R.E., Biswas H.H., Norris P.J., Lanteri M.C. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytometry A 2009, 75:1040-1050.
34. Langenhorst D., Gogishvili T., Ribechini E., Kneitz S., McPherson K., Lutz M.B., et al. Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells. PLoS ONE 2012, 7:e50080.
35. Chaudhry A., Rudensky A.Y. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest 2013, 123:939-944.
36. Sela U., Sharabi A., Dayan M., Hershkoviz R., Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology 2009, 128:395-405.
37. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003, 101:758-765.
38. Cella M., Döhring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997, 185:1743-1751.
39. Vlad G., Chang C.C., Colovai A.I., Vasilescu E.R., Cortesini R., Suciu-Foca N. Membrane and soluble ILT3 are critical to the generation of T suppressor cells and induction of immunological tolerance. Int Rev Immunol 2010, 29:119-132.
40. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
41. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:173-184.
42. Wang L., Larkins N., Jung B., Au N.H., Mammen C. Acute encephalopathy in a kidney transplant recipient following infusion of intravenous immunoglobulin. Transpl Int 2014.
43. Feldmeyer L., Benden C., Haile S.R., Boehler A., Speich R., French L.E., et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol 2010, 90:494-497.
44. Mazer B.D., Al-Tamemi S., Yu J.W., Hamid Q. Immune supplementation and immune modulation with intravenous immunoglobulin. J Allergy Clin Immunol 2005, 116:941-944.
45. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006, 117:525-553.